Toronto, Ontario – July 30, 2026 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.
“PharmAla’s financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry,” said Nick Kadysh, CEO, PharmAla Biotech. “We were pleased to execute an excellent quarter of sales, as well as our transaction with Jupiter Neuroscience, first announced in Q3 and executed as a subsequent event in Q4.”
Financial Highlights:
the three and nine months ended May 31, 2025. Primarily due to the increase in revenue.
“While we have capitalized on opportunities in making strategic product sales, we are far more excited about our recent licensing agreements,” said Will Avery, CFO of PharmAla Biotech. “Long-term, licensing agreements present not only further revenue opportunities but also reflect the potential upside value of our research and development engine.”
Annual General Meeting Update:
PharmAla would like to thank all Shareholder who participated in the Company’s Annual General Meeting, and is pleased that all motions recommended by management were duly passed.